Over the past several years, Chemoswed has developed, scaled up, and validated an efficient process for manufacturing high quality, cGMP compliant WTX101. The sponsor recently reported highly promising results from a 24-week clinical phase II study in patients newly diagnosed with Wilson’s disease.

Jonas Hansson, CEO, commented “We are extremely pleased with the results from this Phase 2 study. We believe that WTX101 may have the potential to improve treatment options for patients with Wilson Disease, a life-long disease for which there has been no innovation for decades.”

Dr Lars Olsson, VP CMC, said “I have enjoyed our collaboration with Chemoswed, which has been very smooth and successful. They have taken on the challenge of developing our rather unusual active ingredient with enthusiasm, transparency, and proficiency. We are well positioned for commercial manufacturing.”

Dr Carl Andersson, marketing manager at Chemoswed, noted “All along we have been excited by the opportunities that WTX101 offer. We congratulate our friends at Wilson Therapeutics on an important milestone.”